• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

p53 在肿瘤免疫的十字路口。

p53 at the crossroads of tumor immunity.

机构信息

Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.

Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY, USA.

出版信息

Nat Cancer. 2024 Jul;5(7):983-995. doi: 10.1038/s43018-024-00796-z. Epub 2024 Jul 15.

DOI:10.1038/s43018-024-00796-z
PMID:39009816
Abstract

The p53 tumor suppressor protein has a plethora of cell-intrinsic functions and consequences that impact diverse cell types and tissues. Recent studies are beginning to unravel how wild-type and mutant p53 work in distinct ways to modulate tumor immunity. This sets up a disequilibrium between tumor immunosurveillance and escape therefrom. The ability to exploit this emerging knowledge for translational approaches may shape immunotherapy and targeted therapeutics in the future, especially in combinatorial settings.

摘要

抑癌蛋白 p53 具有多种细胞内固有功能和后果,影响多种细胞类型和组织。最近的研究开始揭示野生型和突变型 p53 如何以不同的方式调节肿瘤免疫。这在肿瘤免疫监视和逃逸之间造成了失衡。利用这一新兴知识进行转化方法的能力可能会在未来塑造免疫疗法和靶向治疗,特别是在联合治疗环境中。

相似文献

1
p53 at the crossroads of tumor immunity.p53 在肿瘤免疫的十字路口。
Nat Cancer. 2024 Jul;5(7):983-995. doi: 10.1038/s43018-024-00796-z. Epub 2024 Jul 15.
2
Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies.针对 p53 突变癌症的有前途的新工具:体液和基于细胞的免疫疗法。
Front Immunol. 2021 Aug 13;12:707734. doi: 10.3389/fimmu.2021.707734. eCollection 2021.
3
Mutant p53 as an Antigen in Cancer Immunotherapy.突变型p53作为癌症免疫治疗中的一种抗原。
Int J Mol Sci. 2020 Jun 8;21(11):4087. doi: 10.3390/ijms21114087.
4
P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.P53:免疫的守护者因突变成为其破坏者。
Int J Mol Sci. 2020 May 13;21(10):3452. doi: 10.3390/ijms21103452.
5
P53 and The Immune Response: 40 Years of Exploration-A Plan for the Future.P53 与免疫反应:40 年的探索——未来计划。
Int J Mol Sci. 2020 Jan 15;21(2):541. doi: 10.3390/ijms21020541.
6
Modulation of immunosurveillance by tumor-intrinsic genomic alterations.肿瘤内在基因组改变对免疫监视的调节
Immunotherapy. 2017 Dec;9(16):1305-1307. doi: 10.2217/imt-2017-0132.
7
p53: a potential target antigen for immunotherapy of cancer.p53:癌症免疫治疗的潜在靶抗原。
Ann N Y Acad Sci. 2000 Jun;910:223-33; discussion 233-6. doi: 10.1111/j.1749-6632.2000.tb06711.x.
8
p53 mutations in cancer.癌症中的 p53 突变。
Nat Cell Biol. 2013 Jan;15(1):2-8. doi: 10.1038/ncb2641.
9
The role of the MDM2/p53 axis in antitumor immune responses.MDM2/p53 轴在抗肿瘤免疫反应中的作用。
Blood. 2024 Jun 27;143(26):2701-2709. doi: 10.1182/blood.2023020731.
10
Transcription regulation by mutant p53.突变型p53的转录调控
Oncogene. 2007 Apr 2;26(15):2202-11. doi: 10.1038/sj.onc.1210294.

引用本文的文献

1
The Potential Mechanisms of Ochratoxin A in Prostate Cancer Development: An Integrated Study Combining Network Toxicology, Machine Learning, and Molecular Docking.赭曲霉毒素A在前列腺癌发生发展中的潜在机制:一项结合网络毒理学、机器学习和分子对接的综合研究
Toxins (Basel). 2025 Aug 4;17(8):388. doi: 10.3390/toxins17080388.
2
Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery.异鼠李素:抗癌机制及纳米制剂驱动递送的最新进展综述
Int J Mol Sci. 2025 Jul 30;26(15):7381. doi: 10.3390/ijms26157381.
3
Causality-aware graph neural networks for functional stratification and phenotype prediction at scale.

本文引用的文献

1
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.p53 缺失和突变异质性驱动高肿瘤突变负荷的自发小鼠肺癌模型中的免疫抵抗。
Cancer Cell. 2023 Oct 9;41(10):1731-1748.e8. doi: 10.1016/j.ccell.2023.09.006. Epub 2023 Sep 28.
2
p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression.p53 功能获得性突变通过 BRD4 依赖性 CSF-1 表达诱导转移。
Cancer Discov. 2023 Dec 12;13(12):2632-2651. doi: 10.1158/2159-8290.CD-23-0601.
3
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy.
用于大规模功能分层和表型预测的因果感知图神经网络
NPJ Syst Biol Appl. 2025 Aug 12;11(1):92. doi: 10.1038/s41540-025-00567-1.
4
Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target.整合多组学揭示了慢性淋巴细胞白血病中调节性和耗竭性T细胞格局,并确定半乳凝素-9为免疫治疗靶点。
Nat Commun. 2025 Aug 7;16(1):7271. doi: 10.1038/s41467-025-61822-x.
5
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.癌症中的免疫逃逸:机制与前沿治疗方法。
Signal Transduct Target Ther. 2025 Jul 31;10(1):227. doi: 10.1038/s41392-025-02280-1.
6
Functions of Intrinsically Disordered Regions.内在无序区域的功能。
Biology (Basel). 2025 Jul 4;14(7):810. doi: 10.3390/biology14070810.
7
The roles of mutant p53 in reprogramming and inflammation in breast cancers.突变型p53在乳腺癌重编程和炎症中的作用。
Cell Death Differ. 2025 Jul 23. doi: 10.1038/s41418-025-01549-w.
8
Promising therapeutic efficacy and safety of a novel integrin α6-targeting peptide-drug conjugate in lung adenocarcinoma.一种新型整合素α6靶向肽-药物偶联物在肺腺癌中的治疗效果和安全性颇具前景。
Mol Cancer. 2025 Jul 5;24(1):190. doi: 10.1186/s12943-025-02395-7.
9
p53 in colorectal cancer: from a master player to a privileged therapy target.p53与结直肠癌:从主导因素到优先治疗靶点
J Transl Med. 2025 Jun 19;23(1):684. doi: 10.1186/s12967-025-06566-4.
10
The TP53 tumor suppressor gene: From molecular biology to clinical investigations.TP53肿瘤抑制基因:从分子生物学到临床研究
J Intern Med. 2025 Aug;298(2):78-96. doi: 10.1111/joim.20106. Epub 2025 Jun 16.
使用基于T细胞受体的细胞疗法靶向驱动癌基因和其他公共新抗原。
Annu Rev Cancer Biol. 2023;7(1):331-351. doi: 10.1146/annurev-cancerbio-061521-082114. Epub 2023 Jan 25.
4
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.不断演变的肿瘤微环境:从癌症起始到转移灶生长
Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
5
Altered HLA-A2-restricted TP53 epitope induces specific CTL cytotoxicity against hepatocellular carcinoma.改变的 HLA-A2 限制性 TP53 表位诱导针对肝细胞癌的特异性 CTL 细胞毒性。
Eur J Immunol. 2023 May;53(5):e2250054. doi: 10.1002/eji.202250054. Epub 2023 Feb 28.
6
p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression.p53 通过激活 cGAS/STING 细胞质 DNA 感应通路来抑制肿瘤。
Mol Cell. 2023 Jan 19;83(2):266-280.e6. doi: 10.1016/j.molcel.2022.12.023. Epub 2023 Jan 12.
7
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity.衰老重编微环境感应以促进抗肿瘤免疫。
Cancer Discov. 2023 Feb 6;13(2):432-453. doi: 10.1158/2159-8290.CD-22-0528.
8
Drugging p53 in cancer: one protein, many targets.在癌症中靶向 p53:一种蛋白,多个靶点。
Nat Rev Drug Discov. 2023 Feb;22(2):127-144. doi: 10.1038/s41573-022-00571-8. Epub 2022 Oct 10.
9
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.APR-246 通过诱导 p53 表达重塑肿瘤相关巨噬细胞,增强免疫检查点阻断作用。
J Clin Invest. 2022 Sep 15;132(18):e148141. doi: 10.1172/JCI148141.
10
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.采用自体肿瘤浸润淋巴细胞和靶向人实体瘤常见 p53 新抗原的 T 细胞受体工程化 T 细胞的过继细胞疗法。
Cancer Immunol Res. 2022 Aug 3;10(8):932-946. doi: 10.1158/2326-6066.CIR-22-0040.